BioMarin Pharmaceutical Inc.

78.60-0.7000-0.88%Vol 461.47K1Y Perf 2.87%
Sep 24th, 2021 16:00 DELAYED
BID78.60 ASK78.61
Open79.10 Previous Close79.30
Pre-Market- After-Market78.60
 - -  - -%
Target Price
109.14 
Analyst Rating
Strong Buy 1.38
Potential %
38.86 
Finscreener Ranking
★★★★★     62.20
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     57.71
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     78.16
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
33.22 
Earnings Rating
Neutral
Market Cap14.41B 
Earnings Date
4th Nov 2021
Alpha-0.00 Standard Deviation0.08
Beta0.53 

Today's Price Range

78.3479.41

52W Range

71.6592.57

5 Year PE Ratio Range

-487.50-13.60

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
1.08%
1 Month
0.10%
3 Months
-7.30%
6 Months
5.14%
1 Year
2.87%
3 Years
-18.36%
5 Years
-19.30%
10 Years
154.45%

TickerPriceChg.Chg.%
BMRN78.60-0.7000-0.88
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Financial StrengthValueIndustryS&P 500US Markets
3.50
5.30
0.20
0.26
-1.80
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
70.40
-2.20
3.50
-20.20
43.71
RevenueValueIndustryS&P 500US Markets
1.92B
10.45
8.84
12.85
Earnings HistoryEstimateReportedSurprise %
Q02 20210.050.23360.00
Q01 20210.070.29314.29
Q04 2020-0.06-0.0516.67
Q03 2020-0.010.293.00K
Q02 2020-0.100.07170.00
Q01 20200.120.38216.67
Q04 20190.010.09800.00
Q03 20190.120.2283.33
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.11-22.22Negative
12/2021 QR-0.23-35.29Negative
12/2021 FY0.1660.00Positive
12/2022 FY1.38-4.17Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.11
Estimates Count7
EPS Growth Next 5 Years %31.70
Volume Overview
Volume461.47K
Shares Outstanding183.35M
Shares Float142.19M
Trades Count7.92K
Dollar Volume116.61M
Avg. Volume1.12M
Avg. Weekly Volume865.36K
Avg. Monthly Volume1.37M
Avg. Quarterly Volume1.13M

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock closed at 78.6 per share at the end of the most recent trading day (a -0.88% change compared to the prior day closing price) with a volume of 463.16K shares and market capitalization of 14.41B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3059 people. BioMarin Pharmaceutical Inc. CEO is Jean-Jacques Bienaime.

The one-year performance of BioMarin Pharmaceutical Inc. stock is 2.87%, while year-to-date (YTD) performance is -10.37%. BMRN stock has a five-year performance of -19.3%. Its 52-week range is between 71.65 and 92.57, which gives BMRN stock a 52-week price range ratio of 33.22%

BioMarin Pharmaceutical Inc. currently has a PE ratio of 18.00, a price-to-book (PB) ratio of 3.36, a price-to-sale (PS) ratio of 7.40, a price to cashflow ratio of 55.50, a PEG ratio of 2.32, a ROA of 14.57%, a ROC of 16.81% and a ROE of 21.87%. The company’s profit margin is 43.71%, its EBITDA margin is 3.50%, and its revenue ttm is $1.92 Billion , which makes it $10.45 revenue per share.

Of the last four earnings reports from BioMarin Pharmaceutical Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. BioMarin Pharmaceutical Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for BioMarin Pharmaceutical Inc. is Strong Buy (1.38), with a target price of $109.14, which is +38.86% compared to the current price. The earnings rating for BioMarin Pharmaceutical Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioMarin Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioMarin Pharmaceutical Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.19, ATR14 : 1.95, CCI20 : -28.83, Chaikin Money Flow : 0.02, MACD : -0.16, Money Flow Index : 47.90, ROC : 2.48, RSI : 49.77, STOCH (14,3) : 45.57, STOCH RSI : 0.73, UO : 47.42, Williams %R : -54.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioMarin Pharmaceutical Inc. in the last 12-months were: Brian Mueller (Sold 0 shares of value $-189 395 ), Brian Mueller (Sold 6 709 shares of value $533 366 ), Elaine J. Heron (Sold 0 shares of value $-794 700 ), G. Eric Davis (Sold 0 shares of value $-71 761 ), G. Eric Davis (Sold 12 900 shares of value $1 004 654 ), Jean-Jacques Bienaime (Sold 0 shares of value $-3 770 619 ), Jean-Jacques Bienaime (Sold 142 513 shares of value $11 448 862 ), Jeffrey R. Ajer (Sold 7 799 shares of value $606 294 ), Michael G. Grey (Sold 0 shares of value $-132 450 ), Michael G. Grey (Sold 5 000 shares of value $381 400 ), V. Bryan Lawlis (Sold 0 shares of value $-397 350 ), V. Bryan Lawlis (Sold 15 000 shares of value $1 232 325 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
15 (75.00 %)
15 (75.00 %)
15 (75.00 %)
Moderate Buy
2 (10.00 %)
2 (10.00 %)
2 (10.00 %)
Hold
3 (15.00 %)
3 (15.00 %)
3 (15.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.38
Strong Buy
1.38
Strong Buy
1.38

BioMarin Pharmaceutical Inc.

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

CEO: Jean-Jacques Bienaime

Telephone: +1 415 506-6700

Address: 770 Lindaro Street, San Rafael 94901, CA, US

Number of employees: 3 059

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

58%42%

Bearish Bullish

67%33%

News

Stocktwits